Notably, GSK said it recently reduced the list price of Advair HFA by an average ... of those products and the rest of its ...
Hosted on MSN8mon
Drugmaker will cap inhaler costs at $35 per month amid scrutinyThe company also agreed to reduce the list price of some of its inhalers ... Tens of millions of Americans suffer from asthma and COPD and rely on inhalers to breathe — about 25 million ...
Poor treatment of asthma and COPD puts a huge burden on the NHS. For example, £1 billion is spent on asthma treatment in the UK each year and represents 60,000 to 65,000 hospital admissions. In ...
AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late-stage trial success. AZ’s single inhaler, PT010 ...
6mon
Under the leadership of Pam Cheng, the company’s chief sustainability officer and EVP of Global Operations and IT, Breztri ...
Patients with COPD often experience chronic cough, difficulty breathing, and reduced lung function. While the respiratory disease is not curable, it can be treated and managed with medications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback